Snowy Owl Gold Corp is engaged in the acquisition and exploration of gold property assets. The company projects include Golden Eagle, Riviere Lois and Panache Property.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
Unknown
1
100.0%
暂无批准数据
- Sanofi's chief digital officer projects AI can compress drug development timelines from 10–12 years to 5–6 years by simulating clinical trials before they occur. - Industry leaders at theCUBE + NYSE Wired: AI in Bio event emphasized that 90–95% of drugs fail in the clinic, with AI targeting higher probability of clinical success as the key bottleneck. - Multiple biotech companies, including Noetik, Insitro, and Sen-Jam Pharmaceutical, are deploying AI platforms to build causal disease models, digital twins of tumors, and immunomodulators with 200–300% improved success rates. - A unified, governed data foundation is described as the prerequisite for AI precision, with Sanofi treating Snowflake as an operating system to eliminate fragmented data silos.
- Sorcero secured $42.5 million in Series B financing led by NewSpring Capital to expand its AI-powered intelligence platform across medical affairs, safety, and scientific communications segments globally. - The platform serves one-third of the top 30 global pharmaceutical companies, delivering 18x faster insights and improving scientific evidence generation productivity by up to 92%. - Sorcero's medically-tuned AI processes over 263 million publications and 1.3 billion citations globally, achieving 96.1% clinical inclusion accuracy that surpasses FDA regulatory thresholds. - The funding addresses critical industry challenges where 76% of new products secure less than 50% payor coverage within six months and 70% of healthcare professionals believe pharma representatives don't understand their needs.
- Clinical ink has introduced TrialLens, an AI-powered analytics dashboard that provides real-time insights into clinical trial operations, subject behavior, and digital biomarker metrics. - The platform integrates Snowflake's data cloud with AWS technologies (Q, QuickSight, and Bedrock) and features generative AI capabilities that allow teams to investigate clinical data through natural language queries. - TrialLens offers comprehensive visualization of subject physiological data from various devices and provides operational insights to support risk mitigation, trial execution, and site management.
• Polish biotech startup Ingenix has raised €9 million in seed funding to develop an AI-powered platform that simulates clinical drug trials from molecular to population levels. • Founded by former Applica executives Piotr Surma and Adam Dancewicz, Ingenix aims to address the 90% failure rate of pilot drugs despite the pharmaceutical industry's $50 billion annual investment in clinical trials. • The funding round was led by Inovo.vc with participation from OTB Ventures and the International Finance Corporation, positioning Ingenix to potentially deliver the pharmaceutical industry's "GPT moment."
